Figure 1.

In vitro assessment of the pre-erythrocytic activity of M5717-Pyro combination in Pb-Luc-infected HepG2 spheroids. (A) Schematic representation of the static infection platform employing HepG2 spheroids and Pb-Luc sporozoites (not at scale) and the drug exposure mode used for IC₅₀ determination. (B) Dose–response curves and IC₅₀ determination of M5717 (pink) and M5717-Pyro combination (M5717 + Pyro, blue). Cells were plated at a density of 2.5 × 10⁴ cell/well and infected at a cell:spz ratio of 1:2. Infection rate was normalized to that of DMSO-exposed spheroids and results are represented as the mean ± SD of at least three independent experiments. Statistical analysis was performed using an unpaired t test. ** P ≤ 0.01.